omega-3 fatty acid treatment in cardiac syndrome X: a double-blind, randomized, placebo-controlled clinical study

Objective We conducted a clinical trial to examine the effect of omega-3 fatty acids in patients with cardiac syndrome X (CSX). We aimed to evaluate the potential impact of omega-3 fatty acids on endothelial function, oxidative stress, and symptom relief in the CSX. Methods and results Eighteen patients with CSX were enrolled according to a double-blind, randomized, placebo-controlled design. Patients were randomized to omega-3 fatty acids (1440 mg/day, n = 8) or placebo (n = 10) for 4 months. We assessed plasma levels of malondialdehyde (MDA), endothelium-dependent vasodilatation [flow-mediated dilatation (FMD)], endothelium-independent vasodilatation [nitroglycerin-mediated dilatation (NMD)], and status of symptom [score with Seattle Angina Questionnaire (SAQ)] before and after the treatment. After 4 months, patients who were treated with omega-3 fatty acids showed significant increases in the FMD (from 47 +/- 48 to 104 +/- 23%, P<0.05) and NMD (from 51 +/- 53 to 93 +/- 35%, P<0.05) values, and significant decreases in the plasma MDA levels (4.4 +/- 0.86 to 3.35 +/- 0.33 mu mol/l, P = 0.012). SAQ scores were increased significantly in both groups (from 60 +/- 14 to 73 +/- 15%, P<0.05 placebo, from 67 +/- 0 to 81 +/- 9%, P<0.05 treatment group). NMD was correlated negatively with the plasma MDA levels. Conclusion Four months of therapy with a moderate dose of omega-3 fatty acids improved the endothelial function and reduced oxidative stress in patients with CSX. Coron Artery Dis 24:328-333 (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

Yazar Bozcali, Evin
Babalik, Erhan
Himmetoglu, Solen
Mihmanli, Ismail
Toprak, Sadik
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/3029
Tek Biçim Adres 10.1097/MCA.0b013e32835f3005
Konu Başlıkları coronary resistance
endothelial dysfunction
lipid peroxidation
microvascular angina
oxidative stress
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı CORONARY ARTERY DISEASE
Dergi Cilt Bilgisi 24
Dergi Sayısı 4
Sayfalar 328 - 333
Yayın Yılı 2013
Eser Adı
[dc.title]
omega-3 fatty acid treatment in cardiac syndrome X: a double-blind, randomized, placebo-controlled clinical study
Yazar
[dc.contributor.author]
Bozcali, Evin
Yazar
[dc.contributor.author]
Babalik, Erhan
Yazar
[dc.contributor.author]
Himmetoglu, Solen
Yazar
[dc.contributor.author]
Mihmanli, Ismail
Yazar
[dc.contributor.author]
Toprak, Sadik
Yayın Yılı
[dc.date.issued]
2013
Yayıncı
[dc.publisher]
LIPPINCOTT WILLIAMS & WILKINS
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Objective We conducted a clinical trial to examine the effect of omega-3 fatty acids in patients with cardiac syndrome X (CSX). We aimed to evaluate the potential impact of omega-3 fatty acids on endothelial function, oxidative stress, and symptom relief in the CSX. Methods and results Eighteen patients with CSX were enrolled according to a double-blind, randomized, placebo-controlled design. Patients were randomized to omega-3 fatty acids (1440 mg/day, n = 8) or placebo (n = 10) for 4 months. We assessed plasma levels of malondialdehyde (MDA), endothelium-dependent vasodilatation [flow-mediated dilatation (FMD)], endothelium-independent vasodilatation [nitroglycerin-mediated dilatation (NMD)], and status of symptom [score with Seattle Angina Questionnaire (SAQ)] before and after the treatment. After 4 months, patients who were treated with omega-3 fatty acids showed significant increases in the FMD (from 47 +/- 48 to 104 +/- 23%, P<0.05) and NMD (from 51 +/- 53 to 93 +/- 35%, P<0.05) values, and significant decreases in the plasma MDA levels (4.4 +/- 0.86 to 3.35 +/- 0.33 mu mol/l, P = 0.012). SAQ scores were increased significantly in both groups (from 60 +/- 14 to 73 +/- 15%, P<0.05 placebo, from 67 +/- 0 to 81 +/- 9%, P<0.05 treatment group). NMD was correlated negatively with the plasma MDA levels. Conclusion Four months of therapy with a moderate dose of omega-3 fatty acids improved the endothelial function and reduced oxidative stress in patients with CSX. Coron Artery Dis 24:328-333 (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Açıklama
[dc.description]
WOS: 000318154600011
Açıklama
[dc.description]
PubMed: 23425772
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
coronary resistance
Konu Başlıkları
[dc.subject]
endothelial dysfunction
Konu Başlıkları
[dc.subject]
lipid peroxidation
Konu Başlıkları
[dc.subject]
microvascular angina
Konu Başlıkları
[dc.subject]
oxidative stress
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0954-6928
Sponsor YAYINCI
[dc.description.sponsorship]
Turkish Society of Cardiology [2006-3]; Kocak Farma Pharmaceutical Company, Istanbul, Turkey
Sponsor YAYINCI
[dc.description.sponsorship]
This study was supported by a Research Fund of the Turkish Society of Cardiology (fund number 2006-3) and Kocak Farma Pharmaceutical Company, Istanbul, Turkey.
İlk Sayfa Sayısı
[dc.identifier.startpage]
328
Son Sayfa Sayısı
[dc.identifier.endpage]
333
Dergi Adı
[dc.relation.journal]
CORONARY ARTERY DISEASE
Dergi Sayısı
[dc.identifier.issue]
4
Dergi Cilt Bilgisi
[dc.identifier.volume]
24
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1097/MCA.0b013e32835f3005
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/3029
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
11
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
07 Şubat 2024 13:40
Google Kontrol
Tıklayınız
omega-3 patients levels months plasma vasodilatation placebo dilatation randomized treatment symptom endothelial significant stress function oxidative values decreases groups significantly scores increased Objective Artery Wilkins Williams Lippincott vertical Health Kluwer Wolters 328-333 reduced improved moderate
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms